Long-Term Follow-Up of EBT-101 for HIV

Recruiting at 7 trial locations

Overseen By Study Lead at ExcisionBio

Age: 18+

Sex: Male

Trial Phase: Phase 1

Sponsor: Excision BioTherapeutics

Disqualifiers: Did not receive EBT-101

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

9 Participants Needed

Trial Summary

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

What is the purpose of this trial?

This trial involves follow-up for participants who received the EBT-101 treatment in an earlier study. The goal is to monitor their health and the treatment's effects over time.

Research Team

William Kennedy, MD

Principal Investigator

Excision BioTherapeutics

Eligibility Criteria

This trial is for adults with HIV who have previously received the investigational treatment EBT-101 in an earlier study. They must have signed a consent form agreeing to participate and be monitored over time.

Inclusion Criteria

Participants who received the investigational study intervention EBT-101 in a parent study

Willing and able to provide written, signed informed consent

Exclusion Criteria

I have not previously received EBT-101 in any study.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Long-Term Follow-Up

Participants will have follow-up visits every six months until Year 5 post EBT-101 administration

5 years

Follow-up visits every six months

Extended Follow-Up

Participants will have annual follow-up visits on the anniversary of EBT-101 administration until study completion

10 years

Annual follow-up visits

Treatment Details

Interventions

• EBT-101

Trial Overview The focus of this study is on long-term follow-up of patients who were treated with EBT-101, which is a new intervention for HIV. The goal is to observe the extended effects and outcomes after initial treatment.

Participant Groups

Group I: Long Term Follow Up Experimental Treatment 1 Intervention

Participants who received EBT-101 in a parent study will undergo long term follow up

Who Is Running the Clinical Trial?

Excision BioTherapeutics

Lead Sponsor

Trials

2

Recruited

20+